Expertini:GlobalPressReleases&NewswireDistribution®

AbbvieShowcasesEarlyPipelineAnd

ScientificAdvancesInOncologyAtAacr

AnnualMeeting2025

ContactThisPRNews

AboutThisPRNews

Company:PrNewswire

Location:UnitedStates

25-30,2025.

Presentationsincludedatafromnovelinvestigationalmolecules,ABBV-969andABBV-514,acrossarangeofhard-to-treattumor

types.1,2Additionally,newinsightsontreatmentresistanceandnovelbiomarkeridentificationbasedonreal-world-dataanalysesaretobe

presented.3,4,5"Asweseektoadvanceinnovativetherapiesforpeoplelivingwithdifficult-to-treatcancers,ourearly-stageoncologyresearchhelps

laythescientificfoundationforfutureinnovationthatmayaddressprofoundunmetneedsthatmanypatientsexperience,"saidTheodoraS.

Ross,M.D.,Ph.D.,vicepresident,earlyoncologyresearchanddevelopment,AbbVie.

"Byharnessingthelatestscientificbreakthroughsintranslationalresearch,weareadvancingnoveltherapeuticapproachessuchasABBV-969and

ABBV-514,aimingtoimprovecancercareforpatientsworldwide."DataonABBV-969,anovel,dual-targetedADC,withaproprietary,cytotoxic

topoisomerase1inhibitor(Top1i)payloadwillbepresentedinanoralpresentationatthemeeting.1ABBV-969isdesignedtotargettumorcells

expressingSTEAP1and/orPSMAantigens.1ProstatecancercellsmayoverexpressSTEAP1,PSMAorboth,andtheirexpressionisassociatedwith

neckcancerandothersolidtumors,bothasamonotherapyandincombinationwithbudigalimab,aPD-1-blockingantibody

(NCT05005403).2,7,8AdditionalpresentationsattheAACRannualmeetingwillincludereal-world-dataanalysesintwokeyareasofcancerresearch-

treatmentresistanceandbiomarkerdiscovery:Ananalysistocharacterizetheoverlapoffolatereceptoralpha(FRa)expression,abiomarkerfoundin

90percentofovariancancers,withotherbiomarkersthatcouldpotentiallyhelpsupportthedevelopmentofnovelprecisionmedicines.4,9,10This

studyprovidesnewinsightsthatcouldaidtreatmentmatchingforpatientsandinformtreatmentsequencingandcombinationtherapyoptions.4Anew

studythatemployedmulti-omicsapproachestoreal-world-dataanalysis,toidentifyclinicalfeaturesandmolecularmechanismsoflong-termresponse

andacquiredresistancetoimmunotherapyinnon-smallcelllungcancer.3Datashowcasinganovelapproachforinvestigatingrelationshipsbetween

germlinevariants,cancerpatientprognosisandtreatmentresponses,usingelectronichealthrecord-linkedgenomicsdataacrossarangeofsolid

tumortypes.5ThestudyshowsthatcertaingermlinevariantsmayserveaspredictivebiomarkersandhelpadvanceprecisionmedicineR&D

efforts.5FurtherinformationonAbbVieclinicaltrialsisavailableathttps://www.clinicaltrials.gov/.AdditionaldetailsonkeypresentationsatAACRare

Antibodies,IncludingEngineeredAntibodies26025Characterizingspatialexpressionpatternsandprevalenceoffolatereceptoralphainrelationto

otherexistingandemergingovariancancerbiomarkersApril29,2:00–5:00PMCTPosterPosterBoard2Session:PredictiveBiomarkers6/Diagnostic

Biomarkers35910Identifyingcancergermlinevariantsassociatedwithpatientprognosisandresponsebyapplyingclinico-genomicsdataApril30,09:00

AM–12:00PMCTPosterPosterBoard19Session:GenomicProfilingofTumors36638ABBV-969andABBV-514areinvestigationalmedicinesandare

notapprovedbyanyhealthauthorityworldwide.

Theirsafetyandefficacyareunderevaluationaspartofongoingclinicalstudies.AboutABBV-969ABBV-969isaninvestigational,novelantibody-drug

conjugate(ADC)targetingprostate-specificmembraneantigen(PSMA)andsixtransmembraneepithelialantigenoftheprostate1(STEAP1),being

investigatedtotreatmetastaticcastration-resistantprostatecancer(mCRPC).1,6ABBV-969wasdesignedusingadualvariabledomain

immunoglobulin(DVD-Ig)withaproprietarytopoisomerase-1(Top1)inhibitorlinker-drugformat.1AboutABBV-514ABBV-514isaninvestigational

anti-chemokineC-Cmotifreceptor8(CCR8)antibodythatisbeinginvestigatedforthetreatmentofrelapsednon-smallcelllungcancer(NSCLC)and

transformingstandardsofcareforpatientslivingwithdifficult-to-treatcancers.

Weareadvancingadynamicpipelineofinvestigationaltherapiesacrossarangeofcancertypesinbothbloodcancersandsolidtumors.

Wearefocusingoncreatingtargetedmedicinesthateitherimpedethereproductionofcancercellsorenabletheirelimination.

Weachievethisthroughvarious,targetedtreatmentmodalitiesandbiologyinterventions,includingsmallmoleculetherapeutics,antibody-drug

conjugates(ADCs),immuno-oncology-basedtherapeutics,multispecificantibodyandinsituCAR-Tplatforms.

Ourdedicatedandexperiencedteamjoinsforceswithinnovativepartnerstoacceleratethedeliveryofpotentialbreakthroughmedicines.Today,our

expansiveoncologyportfoliocomprisesapprovedandinvestigationaltreatmentsforawiderangeofbloodandsolidtumors.

Weareevaluatingmorethan20investigationalmedicinesinmultipleclinicaltrialsacrosssomeoftheworld'smostwidespreadanddebilitating

cancers.

Asweworktohavearemarkableimpactonpeople'slives,wearecommittedtoexploringsolutionstohelppatientsobtainaccesstoourcancer

thoseexpressedorimpliedintheforward-lookingstatements.

Suchrisksanduncertaintiesinclude,butarenotlimitedto,challengestointellectualproperty,competitionfromotherproducts,difficultiesinherent

intheresearchanddevelopmentprocess,adverselitigationorgovernmentaction,andchangestolawsandregulationsapplicabletoourindustry.

Additionalinformationabouttheeconomic,competitive,governmental,technologicalandotherfactorsthatmayaffectAbbVie'soperationsisset

forthinItem1A,"RiskFactors,"ofAbbVie's2024AnnualReportonForm10-K,whichhasbeenfiledwiththeSecuritiesandExchangeCommission,

asupdatedbyitssubsequentQuarterlyReportsonForm10-Q.

AbbVieundertakesnoobligation,andspecificallydeclines,toreleasepubliclyanyrevisionstoforward-lookingstatementsasaresultofsubsequent

eventsordevelopments,exceptasrequiredbylaw.References:ReillyR.

ABBV-969:Afirst-in-classdual-targetingPSMA-STEAP1drugconjugateforthetreatmentofmetastaticcastrate-resistantprostatecancer.

AbstractND03presentedattheAmericanAssociationforCancerResearchAnnualMeeting,2025.Chicago,Illinois.PaustianAS,GuoL,FengW,etal.

Characterizingspatialexpressionpatternsandprevalenceoffolatereceptoralphainrelationtootherexistingandemergingovariancancer

biomarkers.

Abstract5910presentedattheAmericanAssociationforCancerResearchAnnualMeeting,2025.Chicago,Illinois.WuS,TsuiM,McLaughlinRT,et

al.

Identifyingcancergermlinevariantsassociatedwithpatientprognosisandresponsebyapplyingclinico-genomicsdata.

Abstract6638presentedattheAmericanAssociationforCancerResearchAnnualMeeting,2025.Chicago,Illinois.ClinicalTrials.Gov.

NCT06318273.

AStudytoAssessAdverseEvents,andHowIntravenously(IV)InfusedABBV-969MovesThroughtheBodiesofAdultParticipantsWithMetastatic

Castration-ResistantProstateCancer.

Availableonline.

First-in-humanphase1studyofbudigalimab,ananti-PD-1inhibitor,inpatientswithnon-smallcelllungcancerandheadandnecksquamouscell

carcinoma.

CancerImmunolImmunother.

2022;71(2):417-431.MarkertS,LassmannS,GabrielB,etal.

Alpha-folatereceptorexpressioninepithelialovariancarcinomaandnon-neoplasticovariantissue.

AnticancerRes.

2008;28:3567–72.KalliKR,ObergAL,KeeneyGL,etal.

Folatereceptoralphaasatumortargetinepithelialovariancancer.

GynecolOncol.

2008;108:619–26.Contacts:Media:Sourojit(Jit)Bhowmick,Ph.D.jit.bhowmick@abbvie.comInvestors:LizShealiz.shea@abbvie.comMabel